Gynecomastia and semen abnormalities induced by spironolactone in normal men

Journal of Clinical Endocrinology and Metabolism

Volumn 45, Issue 2, 1977, Pages 255-260

  Caminos Torres, Raul ^a   Ma, Lisa ^a   Snyder, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CANRENOIC ACID; CANRENONE; ESTRADIOL; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; SPIRONOLACTONE; TESTOSTERONE;

ADVERSE DRUG REACTION; CLINICAL STUDY; DRUG THERAPY; GYNECOMASTIA; HUMAN; HYPOPHYSIS TESTIS SYSTEM; IN VITRO STUDY; LIBIDO; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SPERM; SPERMATOZOON ABNORMALITY; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY;

ADULT; CANRENOATE POTASSIUM; CANRENONE; ESTRADIOL; FOLLICLE STIMULATING HORMONE; GYNECOMASTIA; HUMAN; LUTEINIZING HORMONE; MALE; PITUITARY GLAND; SPERM MOTILITY; SPERMATOZOA; SPIRONOLACTONE; SUPPORT, U.S. GOV'T, P.H.S.; TESTIS; TESTOSTERONE;

EID: 0017641194     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-45-2-255     Document Type: Article

References (16)

1. Clark, E., Spironolactone therapy and gynecomastia., JAMA 193: 163, 1965.
2. Spark, R. F., and J. C. Melby, Aldosteronism in hypertension. The spironolactone response test, Ann Intern Med 69: 685, 1968.
3. Adlin, E. V., A. D. Marks, and B. J. Channick, Spironolactone and hydrochlorothiazide in essential hypertension, Arch Intern Med 130: 855, 1972.
4. Douglas, J. C, J. W. Hollifield, and G. W. Liddle, Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide- triamterene combination, JAMA 227: 518, 1974.
5. Menard, R. H., B. Stripp, and J. R. Gillette, Spironolactone and testicular cytochrome P- 450: Decreased testosterone formation in several species and changes in hepatic drug metabolism, Endocrinology 94: 1628, 1974.
6. Huffman, D. H., and D. L. Azarnoff, Effect of spironolactone on metabolic conversion of androgens to estrogens, Clin Res 23: 476A, 1975.
7. Corvol, P., A. Michaud, J. Menard, M. Freifeld, and J. Mahoudeau, Antiandrogenic effect of spironolactones: mechanism of action, Endocrinology 97: 52, 1975.
8. Pita, J. C Jr., M. E. Lippman, E. B. Thompson, and D. L. Loriaux, Interaction of spironolactone and digitalis with the 5a-dihydrotestosterone (DHT) receptor of rat ventral prostate, Endocrinology 97: 1521, 1975.
9. Stripp, B., A. A. Taylor, F. C. Bartter, J. R. Gillette, D. L. Loriaux, R. Easley, and R. H. Menard, Effect of spironolactone on sex hormones in man, J Clin Endocrinol Metab 41: 777, 1975.
10. Sadee, W., M. Dageioglu, and R. Schroder, Pharmacokinetics of spironolactone, canrenone and canrenoate- K in humans, J Pharmacol Exp Ther 185: 686, 1973.
11. Snyder, P. J., J. F. Reitano, and R. D. Utiger, Serum LH and FSH responses to synthetic gonadotropin releasing hormone in normal men, J Clin Endocrinol Metab 41: 938, 1975.
12. Gochman, N., and C. E. Gantt, A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma, J Pharmacol Exp Ther 135: 312, 1962.
13. Paulsen, C. A., In Williams, R. H. (ed.), Textbook of Endocrinology, ed. 5, W. B. Saunders Co., Philadelphia, 1974, p. 332.
14. Snedecor, G. W., and W. G. Cochran, Statistical Methods, ed. 5, Iowa State University Press, Ames, Iowa, 1967, p. 59.
15. Tan, S. Y., and P. J. Mulrow, Interference of spironolactone in 11-deoxycorticosterone radioassays, J Clin Endocrinol Metab 41: 791, 1975.
16. Sadee, W., A. M. Finn, P. Schmiedek, and A. Baethmann, Aldosterone plasma interference by a spironolactone metobolite, Steroids 25: 301, 1975.